Opens in a new tab

GlaxoSmithKline Biologicals v Pfizer (CFI, UPC_CFI_1509/2025, 10 November 2026)

Date10 November 2026
CourtCFI
DivisionThe Hague (NL) Local Division
Type of actionRevocation Action
Case number(s)UPC_CFI_1509/2025; UPC_CFI_620/2025; UPC_CFI_1511/2025
Registry referenceUPC-CFI-0001509/2025
PartiesGlaxoSmithKline Biologicals SA v. C.P. Pharmaceuticals International C.V.; Pfizer Export B.V.; Pfizer B.V.; Pfizer Manufacturing Belgium N.V.; Pfizer Service Company B.V./S.r.l.; Pfizer S.A./N.V.; Pfizer Luxembourg SARL; Pfizer Inc.; Pfizer Corporation Austria Gesellschaft m.b.H; Pfizer ApS; Pfizer Oy; Pfizer S.A.S.; Pfizer Pharma GmbH; Pfizer S.r.l.; Laboratórios Pfizer, Lda.; Pfizer Romania S.R.L.; Pfizer AB; Pfizer, spol. S.r.o.; Pfizer Hellas A.E.; Pfizer, S.L.; Pfizer Croatia d.o.o.; Pfizer Gyógyszerkereskedelmi Kft.; Pfizer Polska Sp. Z.o.o.; Pfizer Trading Polska Sp. Z.o.o.; Pfizer AG; Pfizer AS; BioNTech SE; BioNTech Europe GmbH; BioNTech Manufacturing GmbH; BioNTech Manufacturing Marburg GmbH
LanguageEnglish

Official decision (PDF) · UPC registry entry

Case timeline

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 16 November 2026

Our analysis

Summary

By a decision of 10 November 2026 (UPC_CFI_620/2025, UPC_CFI_1509/2025 and UPC_CFI_1511/2025), The Hague Local Division holds that Pfizer and BioNTech’s Comirnaty vaccines infringe claims 1, 2, 3, 6, 10 and 12 of GSK’s EP 2 590 626, a patent for liposomes used to deliver RNA. Claim 13 is revoked. An injunction is granted for all EPC states except Ireland and the United Kingdom, but its enforceability is deferred until a final decision and then three months to conclude a licence.

Facts and procedure

EP 2 590 626 claims liposomes whose lipid bilayer comprises a lipid having a pKa in the range 5.0 to 6.8, measured as described. GSK sued a group of Pfizer and BioNTech companies (referred to together in the decision as PBNT) for infringement by the vaccines marketed as Comirnaty. The defendants brought counterclaims for revocation. The panel comprised Judges Brinkman (presiding), Kokke (judge-rapporteur), Schilling and Schmidt (technically qualified judge).

Issue

Are the claims to that pKa range valid and infringed by Comirnaty, and, if so, is an injunction of that territorial breadth proportionate where the proprietor does not itself work the patent?

Held

The Division reads the claimed pKa range of 5.0-6.8 together with the measurement method in the claim and the imprecision of ±0.2 stated in the description: the limits are not, in this case, to be treated as rigid cut-offs. It allows partial priorities, following G 1/15: the range 5.0-6.7 may rely on the first priority (6 July 2010), and the upper limit of 6.8 on the second (31 August 2010). WO799, which discloses DLinDMA (pKa 5.8), is not intervening prior art under Article 54(3) EPC for the relevant range, since both titles can claim 6 July 2010.

Common general knowledge is construed restrictively: information qualifies only if it is so elementary, convincing and consensual that the skilled person necessarily knows it. Claims 1, 2, 3, 6, 10 and 12 are maintained. Claim 13, a medical-use claim, is revoked for insufficiency. The group’s integrated operational structure supports a finding of joint infringement: acts in the relevant territory are jointly attributable to the defendants.

The injunction covers all EPC states except Ireland and the United Kingdom. For non-UPCA EU states and Lugano states, it is subject to the condition subsequent set by the Court of Appeal in Fujifilm v Kodak (UPC_CoA_312/2025, 2 June 2026). The operative part further provides, for all non-UPCA countries, that the orders are subject to the condition that the competent national courts do not hold the patent invalid.

On proportionality (paras. 252-256), the grant of an injunction remains the rule, following Edwards v Meril. The Division notes the impact of a market withdrawal on PBNT and on third parties, and GSK’s position as a non-practising proprietor, whose harm can be compensated in damages and by a licence. It nevertheless grants the injunction, but postpones its enforceability, as GSK itself requested: a final decision, then three months to conclude a licence, then notice under R. 118.8. PBNT’s request to extend that period to six months is dismissed.

The defendants are jointly and severally ordered to provide information on infringement from 1 January 2020, to pay an interim award of EUR 2 million, and to pay costs (EUR 1 million in the infringement action, plus court fees, and EUR 750,000 in the counterclaims). Penalty payments of up to EUR 100,000 per day for the injunction and EUR 50,000 for the information order, capped at EUR 50 million, are provided for. The information, interim award, penalties and costs are immediately enforceable, subject to notice under R. 118.8.

Key points for practice

Provisions applied

EPC
Articles 54, 56, 83, 87 and 138
UPCA
Articles 41(3), 42, 52(1), 63, 67, 68 and 69
Brussels I recast and Lugano Convention
Articles 4 and 8(1) (Brussels I recast); Article 6(1) (Lugano), as applied by the Division
Rules of Procedure
Rules 118.8, 125 and 354
Case law cited
G 1/15 (EPO Enlarged Board of Appeal), Fujifilm v Kodak (Court of Appeal, UPC_CoA_312/2025, 2 June 2026), Edwards v Meril (Court of Appeal), BSH v Electrolux (CJEU, C-339/22).

Prepared by Dhenne Avocats from the official decision, consulted on 16 November 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Priority right, Novelty, Counterclaim for revocation

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
English from the language of proceedings
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CFI_1509/2025 official number
  • UPC_CFI_620/2025 official number
  • UPC_CFI_1511/2025 official number

Follow these proceedings

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

  1. 25 February 2026 GlaxoSmithKline Biologicals v Pfizer (CFI, 25 February 2026) Infringement Action · UPC_CFI_620/2025, UPC_CFI_1509/2025, UPC_CFI_1511/2025

    La division refuse de limiter à dix les 42 requêtes subsidiaires de GSK mais en ordonne un tableau, et n'accorde qu'une semaine de prorogation du délai de duplique, fixé au 19 mars 2026.

  2. 17 June 2026 GlaxoSmithKline Biologicals v C.P. Pharmaceuticals International C.V. (CFI, 17 June 2026) Infringement Action · UPC_CFI_620/2025

    Le juge rapporteur resserre les débats (moyens de nullité et requêtes subsidiaires), écarte quatorze antériorités nouvelles, refuse un droit général au contre-interrogatoire des experts et rejette la demande des défenderesses d'accéder au dossier de la procédure parallèle contre Moderna sur le même brevet.

  3. 21 August 2026 GlaxoSmithKline Biologicals v C.P. Pharmaceuticals International C.V. (CFI, 21 August 2026) Infringement Action · UPC_CFI_620/2025

    Le juge rapporteur admet trois pièces tardives en raison de circonstances particulières, refuse de traiter comme une modification du brevet un simple tableau récapitulatif et limite les moyens de nullité et les requêtes subsidiaires débattus à l'audience.

  4. 10 November 2026 GlaxoSmithKline Biologicals v Pfizer (CFI, UPC_CFI_620/2025, 10 November 2026) Infringement Action · UPC_CFI_620/2025, UPC_CFI_1509/2025, UPC_CFI_1511/2025

    La division locale de La Haye juge valables et contrefaites les revendications 1, 2, 3, 6, 10 et 12 du brevet EP 2 590 626, révoque la revendication 13, et prononce une injonction couvrant tous les États de la CBE sauf l'Irlande et le Royaume-Uni, dont l'exécution est différée jusqu'à une décision définitive de la JUB,…

  5. 10 November 2026 GlaxoSmithKline Biologicals v Pfizer (CFI, UPC_CFI_1509/2025, 10 November 2026) Revocation Action · UPC_CFI_620/2025, UPC_CFI_1509/2025, UPC_CFI_1511/2025
  6. 10 November 2026 GlaxoSmithKline Biologicals v Pfizer (CFI, UPC_CFI_1511/2025, 10 November 2026) Revocation Action · UPC_CFI_620/2025, UPC_CFI_1509/2025, UPC_CFI_1511/2025

    La division locale de La Haye juge valables et contrefaites les revendications 1, 2, 3, 6, 10 et 12 du brevet EP 2 590 626, révoque la revendication 13, et prononce une injonction couvrant tous les États de la CBE sauf l'Irlande et le Royaume-Uni, dont l'exécution est différée jusqu'à une décision définitive de la JUB,…

What the record states

Nature of the act
Revocation Action
Outcome (Dhenne Avocats summary)
La division locale de La Haye juge valables et contrefaites les revendications 1, 2, 3, 6, 10 et 12 du brevet EP 2 590 626, révoque la revendication 13, et prononce une injonction couvrant tous les États de la CBE sauf l'Irlande et le Royaume-Uni, dont l'exécution est différée jusqu'à une décision définitive de la JUB, puis trois mois pour conclure une licence.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

  • EP 2 590 626 mentioned in: summary of the decision, Dhenne Avocats analysis Follow this patent
Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 2 590 626
Liposomes with lipids having an advantageous pKa-value for RNA delivery
recorded proprietor: GlaxoSmithKline Biologicals SA
Patent at issue according to the summary or official headnote
Also mentioned in 9 other decision(s): GlaxoSmithKline Biologicals v Moderna Netherlands (CFI, 14 September 2 · GlaxoSmithKline Biologicals v C.P. Pharmaceuticals International C.V. · GlaxoSmithKline Biologicals v C.P. Pharmaceuticals International C.V. · GlaxoSmithKline Biologicals v Moderna Netherlands (CFI, UPC_CFI_616/20 · GlaxoSmithKline Biologicals v Moderna Netherlands (CFI, UPC_CFI_616/20 · GlaxoSmithKline Biologicals v Pfizer (CFI, 25 February 2026) · GlaxoSmithKline Biologicals v Moderna (CFI, 18 February 2026) · GlaxoSmithKline Biologicals v Pfizer (CFI, UPC_CFI_620/2025, 10 Novemb
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: summary of the decision, Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.